HBV

Hepatitis B virus

HBV

Related Products

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

HBV Related Products (366)
Antibodies (2)

By Effects:	Inhibitors (331) Degrader (1) Controls (4) Activators (4) Modulators (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-100029A

Bay 41-4109 racemate	Inhibitor	98.92%
BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.

HY-147269

Fosclevudine alafenamide	Inhibitor	98.05%
Fosclevudine alafenamide (Compound EIDD-02173) is an antiviral agent with an EC₅₀ of 1.71 μM against HBV.

HY-113308S1

Taurolithocholic acid-d₄	Inhibitor	98.36%
Taurolithocholic acid-d₄ is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.

HY-105098

Lobucavir	Inhibitor
Lobucavir (BMS-180194; SQ 34514)，a nucleoside analogue，is an antiviral agent. Lobucavir shows a broad spectrum of activity against HBV，HIV/AIDS，and α，β，and γ herpes viruses including CMV，herpes-simplex，varicella-zoster，and Epstein-Barr virus.

HY-16679

Helioxanthin derivative 5-4-2	Inhibitor	99.80%
Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.

HY-N0063R

Punicalagin (Standard)	Inhibitor
Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19.

HY-106233B

Tiviciclovir hydrochloride	Inhibitor	99.36%
Tiviciclovir (AM188) hydrochloride is an antiviral guanosine analog and a hepatitis B virus inhibitor.

HY-131603B

Lamivudine triphosphate TEA	Inhibitor
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.

HY-186131

Val-CDCA	Inhibitor
Val-CDCA is a chenodeoxycholate (CDCA) and C-24 L-Valine (HY-N0717) conjugate. Val-CDCA inhibits taurocholate uptake in human NTCP-stably transfected HEK293 cells. Val-CDCA can be used for HBV infection.

HY-N0058R

4,5-Dicaffeoylquinic acid (Standard)	Inhibitor
4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects.

HY-113308AR

Taurolithocholic acid sodium salt (Standard)	Inhibitor
Taurolithocholic acid (sodium salt) (Standard) is the analytical standard of Taurolithocholic acid (sodium salt). This product is intended for research and analytical applications. Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.

HY-N8153

Glycosmisic acid	Inhibitor
Glycosmisic acid, a natural compound, possesses anti-HBV activity.

HY-113308AS

Taurolithocholic acid-d₄ sodium	Inhibitor	99.4%
Taurolithocholic acid-d₄ (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.

HY-19447A

Besifovir Dipivoxil maleate	Inhibitor
Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies^[2]

HY-144319

SHR5133	Inhibitor
SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC₅₀=26.6 nM).

HY-139574

Firzacorvir	Inhibitor
Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC₅₀ < 1 μΜ.

HY-B0250A

Lamivudine salicylate	Inhibitor
Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.

HY-P990924

Libevitug
HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).

HY-159160

HBV-IN-46	Inhibitor
HBV-IN-46 (compound 1.6) is an active metabolite. HBV-IN-46 is a HBV S-antigen inhibitor, with an EC₅₀ of 2.6 nM.

HY-144320

HBV-IN-17	Modulator
HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC₅₀ of 511 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.

HBV

HBV

HBV Related Products (366)

Antibodies (2)

HBV Related Products (366):